Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
Yoshino T, Oki E, Misumi T, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Sakamoto Y, Shiozawa M, Nishi M, Horiuchi T, Yamagishi H, Sakamoto J, Mizushima T, Ohtsu A, Mori M. Yoshino T, et al. Among authors: shiozawa m. J Clin Oncol. 2022 Oct 10;40(29):3419-3429. doi: 10.1200/JCO.21.02628. Epub 2022 May 5. J Clin Oncol. 2022. PMID: 35512259 Clinical Trial.
The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery.
Watanabe T, Morinaga S, Akaike M, Numata M, Tamagawa H, Yamamoto N, Shiozawa M, Ohkawa S, Kameda Y, Nakamura Y, Miyagi Y. Watanabe T, et al. Among authors: shiozawa m. Eur J Surg Oncol. 2012 Nov;38(11):1051-7. doi: 10.1016/j.ejso.2012.08.008. Epub 2012 Sep 6. Eur J Surg Oncol. 2012. PMID: 22959167
Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
Aoyama T, Katayama Y, Murakawa M, Atsumi Y, Yamaoku K, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Yamamoto N, Oshima T, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Aoyama T, et al. Among authors: shiozawa m. Cancer Chemother Pharmacol. 2015 Jun;75(6):1115-20. doi: 10.1007/s00280-015-2736-5. Epub 2015 Mar 29. Cancer Chemother Pharmacol. 2015. PMID: 25821166
Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1.
Numata K, Oshima T, Sakamaki K, Yoshihara K, Aoyama T, Hayashi T, Yamada T, Sato T, Cho H, Shiozawa M, Yoshikawa T, Rino Y, Kunisaki C, Akaike M, Imada T, Masuda M. Numata K, et al. Among authors: shiozawa m. J Cancer Res Clin Oncol. 2016 Feb;142(2):415-22. doi: 10.1007/s00432-015-2039-6. Epub 2015 Sep 3. J Cancer Res Clin Oncol. 2016. PMID: 26337161
A Phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis: Japan Clinical Oncology Group Study JCOG1310 (PRECIOUS study).
Ohue M, Iwasa S, Kanemitsu Y, Hamaguchi T, Shiozawa M, Ito M, Yasui M, Katayama H, Mizusawa J, Shimada Y; Colorectal Cancer Study Group/Japan Clinical Oncology Group. Ohue M, et al. Among authors: shiozawa m. Jpn J Clin Oncol. 2017 Jan;47(1):84-87. doi: 10.1093/jjco/hyw140. Epub 2016 Sep 21. Jpn J Clin Oncol. 2017. PMID: 27655905 Free PMC article. Clinical Trial.
Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial.
Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K, Ohue M, Ota M, Akazai Y, Shiozawa M, Yamaguchi T, Bandou H, Katsumata K, Murata K, Akagi Y, Takiguchi N, Saida Y, Nakamura K, Fukuda H, Akasu T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Fujita S, et al. Among authors: shiozawa m. Ann Surg. 2017 Aug;266(2):201-207. doi: 10.1097/SLA.0000000000002212. Ann Surg. 2017. PMID: 28288057 Clinical Trial.
Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer.
Kotaka M, Yamanaka T, Yoshino T, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M. Kotaka M, et al. Among authors: shiozawa m. ESMO Open. 2018 Apr 24;3(3):e000354. doi: 10.1136/esmoopen-2018-000354. eCollection 2018. ESMO Open. 2018. PMID: 29713499 Free PMC article.
A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.
Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T. Satake H, et al. Among authors: shiozawa m. Oncotarget. 2018 Apr 10;9(27):18811-18820. doi: 10.18632/oncotarget.24702. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721163 Free PMC article.
453 results